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Introduction
The effects of the Angiotensin II/Angiotensin II type 1 receptor (AT 1 R) are dependent on reactive oxygen species (ROS) production, which are stimulated by NADPH oxidase activation. ROS act as signalling molecules that mediate Angiotensin II-dependent signal transduction pathways [1, 2] . Data from in vivo and in vitro studies prove that locally generated Angiotensin II in proximal tubules (PT) induces renal injury through NADPH oxidase-dependent ROS production [3] [4] [5] [6] .
A role for the renin-angiotensin system in the development and/or maintenance of hypertension has been demonstrated in spontaneously hypertensive rats (SHR) [7] . mechanisms which are critical for renal injury [8] .
Cloned from the kidney, Nox4 belongs to the Nox family of NADPH oxidases [9, 10] . Importantly, Nox4 is associated with mesangial cell, tubular cell or renal interstitial mechanisms by which Nox4 is regulated in the kidney have not been determined. Caveolin-1 plays an important role as a platform for the compartmentalization of redox signaling events through NADPH oxidase-dependent production of ROS [12] . Thus, caveolin-1 is involved in Angiotensin II-induced NADPH activation in the kidney. Previously, we studied how caveolin-1 and Hsp70 possibly contribute to Nox4 expression regulation in SHR PT. We with caveolin-1. The translocation of Hsp70 to PT membranes in Losartan treated SHR might exert a cytoprotective effect through Nox4 downregulation [13] .
In SHR vascular smooth muscle cells (VSMCs), we reported on how a functional association of Hsp70 with Nox4/p22 phox provides a mechanism, which explains an antioxidative effect of Losartan along with subsequent cytoskeletal integrity modulation [14] .
Hsp70 regulates a diverse set of signaling pathways through its interaction with proteins [15] . Carboxy terminus of Hsp70 interacting protein (CHIP), is a cytoplasmic protein that interacts with Hsp70 through its tetratricopeptide repeat domain (TPR), whereas its U-box domain contains its E3 ubiquitin ligase activity. CHIP regulates the Hsp70 chaperone function in part by driving the molecular triage decision, which determines whether proteins enter the productive folding pathway or result in client substrate ubiquitination and proteasomal degradation [16] .
Losartan down regulation of Nox4 levels is not clearly understood, here we analyze Hsp70 and CHIP involvement.
We identify that indeed Hsp70 and CHIP are Nox4-interacting proteins, which promote its ubiquitination and proteasomal degradation within Losartan effect on SHR PTCs.
Materials and Methods

Reagents
Antibodies against Megalin, caveolin-1 and AT 1 R were provided by Santa Cruz Biotechnology (Santa Cruz, CA, USA) and against Ubiquitin by Millipore (California).
Animals
Spontaneously Hypertensive Rats (SHR) and Wistar-Kyotto (WKY) male rats (8-10 weeks old) were used. Indirect systolic blood pressure was measured by the tail cuff method prior to experimentation using (Grass Medical Instruments). The average of 3 pressure readings was recorded. Body weight and systolic blood pressure are included in Table 1. 4% paraformaldehyde, washed with PBS and blocked with 50 mM NH 4 Cl, permeabilized with 0.05% saponin/0.5% BSA in PBS and incubated over night with primary antibodies as below, washed and incubated
The primary antibodies against Megalin, Hsp70, Nox4, CHIP and ubiquitin were used in a 1:100 dilution. The secondary antibodies used were Cy3-conjugated anti-mouse and Alexa 488-conjugated anti-rabbit co-localization from at least 50 cells were examined in each group in three independent experiments. PTCs were treated with AII or Losartan as previously described. The lucigenin derived chemiluminescence assay was performed to determine NADPH oxidase activity in membrane fractions [21] . Simon-OHM, Germany). Basal lectures in absence of NADPH was subtracted from each reading. Activity was expressed as percentage of arbitrary lights units. All assays were performed in duplicate.
Labsystems) at an excitation wavelength of 485 nm and an emission wavelength of 538 nm. Apocynin 50 mM was used as a negative control. were performed in duplicate. 
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Data are presented as means ± SEM from at least 3 independent experiments. Groups were compared using one-way analysis of variance (ANOVA). Bonferroni post hoc test was used to compensate for multiple CA, USA).
Results
1
As to examine caveolin-1 and AT 1 R protein levels, immunoblot analysis was performed CHIP, an Hsp70-associated E3 ubiquitin ligase, promotes protein degradation through the 26 S proteasome [16] . We hypothesized that the AT 1 R blockage would mediate Hsp70 translocation, the chaperone involved in its antioxidative mechanism. We found that Losartan increased Hsp70 expression in SHR PTC membranes when compared with SHR PTC (C) and (AII) membranes.
translocates to PTC membranes. Moreover, increased CHIP expression was shown in SHR PTC membranes after Losartan treatment when compared with PTC membranes stimulated . The lower Nox4 protein levels and the absence of differences allow us to suggest that Hsp70/CHIP interaction may be involved in Nox4 proteasomal degradation after AT 1 R blockage.
treatment
In order to explore the potentially direct relationship between Nox4 and Hsp70/CHIP, Previously treated membrane fractions from SHR and WKY PTCs were immunoprecipitated with anti-Nox4 antibody to assess the possibility that Hp70/CHIP and Nox4 may become physically associated on AT 1 R inhibition. The immunoprecipitates were then subjected to western blot analysis, with mAbs against Hsp70, CHIP and Nox4. As shown interact with decreased Nox4 immunoprecipitation in the membrane fractions. Conversely, increased membrane Nox4 and lower Hsp70 and CHIP protein expression were shown in SHR PTCs (AII). downregulated Nox4 exhibiting a punctate staining in a perinuclear distribution and at the plasma membrane in a pattern similar to the distribution of Nox4 in SHR PTCs (L) and Nox4 labeling was also shown around the nucleus. A clear overlap between increased Nox4 and CHIP with punctuate staining in a perinuclear distribution was These results reveal that both Hsp70 and CHIP are linked to a decrease in Nox4 expression, which probably induces Nox4 ubiquitination when on route to its proteosomic degradation.
In order to further validate the association between Hsp70/CHIP and Nox4, SHR PTCs were transfected with shHsp72-pSIREN-RetroQ vector to transiently silence Hsp72 (inducible fraction of Hsp70) expression and then exposed to the different treatments.
analysis in SHR showed that Hsp72 knockdown led to higher Nox4 protein levels by 35% in PTCs (AII) and by 25% in (L+AII) treated PTCs with decreased CHIP protein levels by 35% in PTCs (L) when related to ev PTCs. Nox4 protein levels in transfected SHR PTCs (L) resembled those of the transfected PTCs at basal condition Nox4 staining was observed in a perinuclear homogeneous pattern of distribution in (L) when related to ev PTCs. Nox4 intense staining in a dotted pattern was shown in transfected SHR PTCs (AII).
Hsp72 silencing of SHR PTCs, Losartan could not prevent an Angiotensin II enhanced Nox4 expression.
To determine whether Hsp70 could be involved in the regulation of PTCs oxidase functioning, we measured NADPH oxidase activity and ROS production in Hsp72 knockdown PTCs.
Transfected PTCs with the plasmid to silence Hsp72 showed a higher NADPH oxidase activity and ROS production at basal conditions. was sustained for up 900ms after Ang II addition. Apocynin, a selective inhibitor of NADPH oxidase, completely abolished the Ang II-stimulated response indicating that NADPH oxidase is the source of intracellular ROS (data not shown). The pre-exposure of SHR PTCs
In SHR PTCs (L) and (L+AII), the Hsp72 silencing caused a near two-fold (L) and threetime-dependent intracellular ROS generation when compared with ev PTCs and non silenced Losartan did not impair either NADPH oxidase activity or ROS generation in Hsp72 knockdown SHR PTCs. In sum, our data show that Hsp70 is involved in the Losartan antioxidative effect.
In order to investigate the mechanism underlying Hsp70-mediated Nox4 downregulation, we studied the effect of Hsp70 on Nox4 ubiquitination and proteasomal degradation. SHR PTCs stimulated with AII or treated with Losartan, were exposed to the proteasome inhibitor MG132 to block degradation of ubiquitinated proteins. Immunoprecipitated Nox4 in SHR these proteins, in PTCs (L) exposed to MG132 treatment demonstrates an inhibited Nox4 protein degradation. Thus, the increased ratio of Nox4/CHIP reveals Nox4 ubiquitination MG132 showed higher ubiquitinated Nox4 immunostaining with a perinuclear distribution Hsp72 knockdown PTCs reveal decreased Nox4/Ubiquitin colocalization resulting in Nox4 upregulation because of the ubiquitination In conjunction with these observations, Hsp70/CHIP promotes ubiquitinization and degradation of Nox4 through a proteasome-dependent pathway.
Discussion
We identify a novel role for Hsp70 as a negative regulator of Nox4. Hsp70/CHIP mediates the ubiquitination and proteasomal degradation of Nox4 thereby inhibiting Nox4-dependent protein expression, which is included within the Losartan antioxidative effect on SHR PTCs.
AT 1 R activation in PT by locally produced AII plays an important role in the pathogenesis of hypertension and renal injury.
AII stimulation promotes AT 1 receptor from the membrane fractions into caveolin-1-enriched lipid rafts. This interaction represents an important target for the dynamic control of receptor signalling [22, 23] . Addressing SHR PTCs, we showed that higher AT 1 R protein levels were induced by the AII association with a slight reduction in caveolin-1 protein levels whereas Losartan treatment decreased AT 1 R and enhanced caveolin-1 protein levels. It is possible that AII stimulation results in caveolae internalization and the translocation to intracellular compartments in which the protein is degraded [22, 24] . Signal-transducing molecules bind to caveolin-1, functioning as redox signaling events through NADPH oxidase-dependent production of ROS [25, 26] . Nox4, which is abundantly expressed in kidney PT cells [10] , is functionally linked to oxygen sensing, is implicated as a major source of renal ROS [27, 28] . Notwithstanding, the mechanism whereby Nox4 activity is regulated remains unclear.
Here, we investigate the role of Hsp70 in the mechanism responsible for the effect of Losartan on ROS through its negative regulation of Nox4. Hsp70 plays a critical role in the recovery of cells from stress [29] . In doing so, Hsp70 facilitates competing pathways of protein folding and degradation [30, 31] , which provides cellular protection by decreased oxidative stress [15] .
As support to this statement, the association of Hsp70 with NADPH, quinone oxidoreductase 1, was demonstrated to play an important role in the stability and functionality of the protein [32] . We provided evidence for the translocated Hsp70 and Nox4 downregulation interaction in SHR microdiseccted proximal tubule membranes after AT 1 R blockage [13] .
It is known that Hsp70 promotes the proteasomal degradation of proteins by recruiting the ubiquitin ligase CHIP, a key component of the chaperone-dependent quality control mechanism [33, 34] . they are partially or frankly misfolded, as is the case for most proteins binding to Hsp70 through exposed hydrophobic residues [16, 35] . In this way, Nox4 is roughly divided in two large domains: an N-terminal cluster of hydrophobic membrane-spanning sequences, and a C-terminal protein domain [36] .
Our results demonstrate that Losartan induces the physical association between the higher amounts of Hsp70/CHIP that co-precipitated with lower Nox4 as an effect of Hsp70/ CHIP interaction with Nox4 in SHR PTC membrane fractions. Nox4 protein downregulation and the unchanging Nox4 gene expression in SHR PTCs (L) suggest a chaperone involvement with Nox4 was shown in (L) and (L+AII)-treated SHR PTCs. The enhanced Hsp70 and CHIP expression contrasts with the lower Nox4 labelling occurring at the PTCs (L). Conversely, Hsp72 knockdown impaired the decay of Nox4 protein levels and decreased CHIP expression despite Losartan treatment. This shows that Hsp70 protein directly interacts with Nox4 and mediates selective Nox4 degradation by its association with CHIP. Hsp72 silencing in SHR PTCs (L) lead to similar values of NADPH oxidase activity and ROS generation as it does for transfected SHR PTCs (C). SHR increased oxidative activity in Hsp72 absence due to the ability of the plasmid vector to transiently silence PTCs.
Taken together, these loss-of-function data indicate that Hsp70 is directly involved in Nox4 regulation through the physical and functional interactions that come under the antioxidative effect of Losartan.
Of note, CHIP acts to tilt the folding-refolding machinery toward a degradative pathway and it serves as a link between the chaperone and proteasome system; and, a recent study recruitment the E3 ubiquitin ligase CHIP, as a molecular mechanism in prolonged hypoxia [37] .
The carboxy terminus of Hsp70-interacting protein (CHIP), a member of E3 ubiquitin ligase, functions as a link between Hsp70 and the proteasome systems, playing a vital role in maintaining the protein homeostasis in the cytoplasm [35] .
Our results show that Hsp70 and E3 ubiquitin ligase CHIP interact with Nox4, by inducing its ubiquitination and subsequent proteasomal degradation in the presence of Losartan.
In this regard, PTCs exposed to the proteasome inhibitor MG132 blocked degradation of ubiquitinated Nox4, even with Losartan treatment. Hence, the higher Nox4/CHIP ratio that the increased colocalization of Nox4 with Ubiquitin following MG132 exposure was due to its ubiquitination reduction, regardless of Losartan treatment. These results indicate that Hsp70 and CHIP selectively regulate the protein stability of Nox4 in the presence of
In conclusion, our data demonstrate that after AT 1 R blockage, Hsp70 interacts and cooperates with CHIP to regulate Nox4 ubiquitination and degradation providing a possible explanation for the mechanism that drives the Losartan antioxidative effect.
This study provides new insights into the mechanisms responsible for Losartan therapeutic intervention against oxidative stress-mediated renal tubular injury. 
